CagriSema (Cagrilintide/Semaglutide)
Out of stock
We will notify you as soon as it becomes available.
-
Description
-
Related Products
-
Related Conditions
Fact Table
| Fact Table | |
|---|---|
| Formula | Cagrilintide: C294H466N82O84 · Semaglutide: C187H291N45O59 |
| License | Not yet approved (Phase 3 trials ongoing) |
| Bioavailability | Subcutaneous administration – systemic exposure established |
| Legal status | Investigational |
| Chemical Name | Cagrilintide and semaglutide |
| Elimination half-life | Cagrilintide: ~163 hours · Semaglutide: ~165 hours |
| Dosage (Strength) | Investigational doses: Cagrilintide 2.4 mg + Semaglutide 2.4 mg weekly |
| Pregnancy | Not recommended – insufficient human data |
| Brands | CagriSema (developmental) |
| Protein binding | High (>99% for both components) |
| PubChem CID | Cagrilintide: Not available · Semaglutide: 56843341 |
| MedlinePlus | Not listed |
| ChEBI | Semaglutide: CHEBI:145346 · Cagrilintide: Not listed |
| ATC code | Not assigned |
| DrugBank | Semaglutide: DB13928 · Cagrilintide: Not listed |
| KEGG | Semaglutide: D11004 · Cagrilintide: Not available |
| Routes of administration | Subcutaneous injection (once weekly) |
CagriSema represents a cutting-edge advancement in metabolic treatment, combining cagrilintide and semaglutide to deliver potent weight loss and glucose control benefits. As an injectable therapy under investigation for use in obesity and type 2 diabetes, CagriSema demonstrates superior efficacy compared to its individual components. With increasing interest from patients and clinicians alike to buy CagriSema, the treatment holds promise for those requiring substantial weight management support.
Directions
Administered once weekly via subcutaneous injection, CagriSema involves a structured titration protocol to ensure optimal tolerance. Dosage and administration guidelines must be followed precisely, under medical supervision. For those seeking CagriSema weight loss, adherence to prescribed lifestyle adjustments is essential to maximize therapeutic success.
Ingredients
This dual-agent therapy includes:
- Cagrilintide, acting to enhance satiety and delay gastric emptying
- Semaglutide, promoting insulin secretion and appetite suppression via GLP-1 receptor activity
Together, these ingredients create a synergistic mechanism supporting improved metabolic function and weight reduction, a core appeal of CagriSema for weight loss strategies.
Cautions
Patients with prior episodes of pancreatitis, significant renal dysfunction, or cardiovascular instability require cautious evaluation before initiating CagriSema. Cost considerations vary—those concerned with the CagriSema cost should consult their provider or pharmacist to explore reimbursement options or financial assistance programs. Concomitant use with other GLP-1 receptor agonists or amylin-based therapies should be avoided.
Contraindications
CagriSema must not be used in patients with a known history of medullary thyroid carcinoma, MEN 2, or hypersensitivity to any active or inactive ingredient in the formulation. Additional contraindications may apply depending on individual health profiles and should be reviewed by a physician.
Side Effects
Frequently reported side effects include:
- Nausea
- Vomiting
- Constipation
- Diarrhea
- Abdominal discomfort
- Injection site irritation
Infrequent but serious risks include pancreatitis, allergic reactions, or thyroid abnormalities, warranting regular clinical follow-up.
Frequently Asked Questions about CagriSema
What is CagriSema?
CagriSema is an investigational combination therapy of cagrilintide and semaglutide being developed for weight management and type 2 diabetes.
How does CagriSema work?
It combines two hormones: semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analog). Together, they help reduce appetite, slow digestion, and improve blood sugar control.
What is CagriSema used for?
CagriSema is being studied for use in adults with obesity or overweight, with or without type 2 diabetes, to support weight loss and improve blood sugar levels.
How is CagriSema taken?
CagriSema is given as a once-weekly injection under the skin. Always follow your healthcare provider’s instructions.
What are common side effects of CagriSema?
Nausea, vomiting, constipation, and decreased appetite are common. These are typically mild to moderate and may improve over time.
Is CagriSema approved yet?
As of now, CagriSema is still in clinical trials and not yet approved for general use. Approval timelines depend on trial outcomes and regulatory review.
How is CagriSema different from semaglutide alone?
CagriSema adds cagrilintide to semaglutide, aiming to enhance weight loss and appetite suppression more than semaglutide alone.
Can CagriSema be used with other diabetes medications?
This will depend on your individual treatment plan. Your healthcare provider will determine safe combinations.
What happens if I miss a dose?
If you miss a dose, take it as soon as possible within a few days. If too much time passes, wait until your next scheduled dose. Ask your provider for specific guidance.
Who should not use CagriSema?
People with a history of certain conditions—like medullary thyroid cancer or pancreatitis—may not be good candidates. Your doctor will assess risks based on your health history.
